TLP
XFOR icon

Tri Locum Partners’s X4 Pharmaceuticals XFOR Stock Holding History

Tri Locum Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-208,250
Closed -$6.81M – 61
2023
Q3 		$6.81M Buy
208,250
+71,585
+52% +$3.12M 2.19% 16
2023
Q2 		$7.95M Buy
136,665
+7,382
+6% +$379K 2.96% 13
2023
Q1 		$3.37M Buy
129,283
+5,732
+5% +$168K 1.03% 28
2022
Q4 		$3.68M Buy
123,551
+40,084
+48% +$1.9M 1.63% 24
2022
Q3 		$4.28M Buy
83,467
+25,524
+44% +$882K 1.22% 29
2022
Q2 		$1.68M Buy
57,943
+690
+1% +$26.2K 0.69% 29
2022
Q1 		$3.01M Buy
57,253
+4,621
+9% +$265K 1.17% 27
2021
Q4 		$3.62M Buy
+52,632
New +$6.66M 1.45% 19

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $694M AUM 79.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $597M AUM 51.11% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return